Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Sponsor Condition of Interest |
---|
TheraSphere With Durvalumab and Tremelimumab for HCC
Boston Scientific Corporation
Hepatocellular Carcinoma
The objective of the ROWAN clinical study is to assess the efficacy of local tumor
control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab. expand
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab. Type: Interventional Start Date: Nov 2023 |
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Prothena Biosciences Ltd.
Light Chain (AL) Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care
compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis. expand
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis. Type: Interventional Start Date: Aug 2021 |
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Advanced Malignant Solid Neoplasm
Anorexia
Hematopoietic and Lymphoid Cell Neoplasm
This phase III trial compares the effects of olanzapine versus megestrol acetate in
treating loss of appetite in patients with cancer that has spread to other places in the
body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find
out if olanzapine is better than the... expand
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss. Type: Interventional Start Date: Jan 2022 |
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Octapharma
Congenital Antithrombin Deficiency
Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic
events (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ
for surgical procedures or parturition. expand
Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition. Type: Interventional Start Date: Jul 2022 |
Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular...
Abiomed Inc.
Left Ventricular Dysfunction
Coronary Artery Disease
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device
during high-risk PCI in patients with reduced left-sided heart function will result in an
improvement in symptoms, heart function and health after a heart procedure compared to
the current standard of care. expand
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care. Type: Interventional Start Date: Apr 2021 |
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Yale University
Intracerebral Hemorrhage
Atrial Fibrillation
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the
composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in
patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in... expand
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale. Type: Interventional Start Date: Jan 2020 |
Focused Ultrasound for the Complex Patient
Washington D.C. Veterans Affairs Medical Center
Opioid Use Disorder
Chronic Back Pain
Anxiety
The goal of this clinical trial is to to inhibit the anterior insula (AI) with low
intensity focused ultrasound (LIFU) to determine the causal role for the AI in pain
processing, anxiety, and opiate cue-induced craving. The main question[s] it aims to
answer are:
- the safety and tolerability... expand
The goal of this clinical trial is to to inhibit the anterior insula (AI) with low intensity focused ultrasound (LIFU) to determine the causal role for the AI in pain processing, anxiety, and opiate cue-induced craving. The main question[s] it aims to answer are: - the safety and tolerability of LIFU delivered bilaterally to AI compared to sham stimulation in individuals with opiate use disorder (OUD), anxiety, and chronic back pain - the effects of LIFU vs sham on measures of pain processing, anxiety symptoms, and opiate cue-induced craving Participants will undergo anatomical MRI, neurological assessment, clinical assessment and patient query to assess the safety and tolerability of LIFU vs sham. Type: Interventional Start Date: Jan 2024 |
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Veralox Therapeutics
Thrombocytopenia, Immune
Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a
12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia
(HIT). Participants with suspected HIT will receive the usual standard of care, and will
be assigned randomly to either VLX-1005 or... expand
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding. Type: Interventional Start Date: Sep 2023 |
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
AtriCure, Inc.
Ischemic Stroke
Systemic Embolism
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority
trial. The objective of this trial is to evaluate the effectiveness of left atrial
appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial
embolism in subjects undergoing cardiac... expand
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke. Type: Interventional Start Date: Jan 2023 |
Evaluation of the Safety and Efficacy of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis
Electra Therapeutics Inc.
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of
excessive immune activation. ELA026 is a fully human IgG1 SIRP-directed monoclonal
antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose
of this study is to assess the safety,... expand
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with secondary hemophagocytic lymphohistiocytosis. Type: Interventional Start Date: May 2022 |
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management...
Reprieve Cardiovascular, Inc
Acute Decompensated Heart Failure
The objective of this study is to prospectively compare decongestive therapy administered
by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients
diagnosed with acute decompensated heart failure (ADHF). The main objective is to
determine if the Reprieve DMS can more... expand
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy. Type: Interventional Start Date: Jul 2022 |
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
Aortic Aneurysm, Abdominal
Juxtarenal Aortic Aneurysm
Extent IV Thoracoabdominal
Pararenal Aneurysm
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and
effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with
the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2
for the treatment of patients with... expand
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries. Type: Interventional Start Date: Dec 2023 |
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
PolyNovo Biomaterials Pty Ltd.
Burns
This is a multi-center, pivotal study to assess the safety and effectiveness of a new
method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM). expand
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM). Type: Interventional Start Date: Sep 2021 |
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in...
Hackensack Meridian Health
Triple Negative Breast Cancer
The probability of pCR in TNBC patients receiving standard of care neoadjuvant
chemotherapy treatment is associated with the dominance of specific intestinal and
intratumoral microbiota that promote anti-tumor immunosurveillance. expand
The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance. Type: Observational Start Date: Aug 2017 |
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Afimmune
Sickle Cell Disease
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in
adult SCD patients who are aged ≥18 years. expand
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years. Type: Interventional Start Date: Jan 2024 |
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement...
Nuvalent Inc.
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and
tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the
antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid
tumors.
Phase 1 will evaluate the overall... expand
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors. Type: Interventional Start Date: Jun 2022 |
Clinical Trial of Approaches to Prostate Cancer Surgery
Weill Medical College of Cornell University
Prostate Cancer
This is a prospective, randomized controlled trial to compare cancer control and
health-related quality of life following pelvic fascia-sparing radical prostatectomy
versus standard radical prostatectomy.
The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have
similar... expand
This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have similar cancer control (primary outcome) and sexual function outcomes; and significantly better urinary function, penile shortening/deformity and inguinal hernia risks as compared to radical prostatectomy. Type: Interventional Start Date: May 2023 |
Comparing Two Methods to Follow Patients With Pancreatic Cysts
ECOG-ACRIN Cancer Research Group
Pancreatic Carcinoma
The purpose of this study is to compare the two approaches for monitoring pancreatic
cysts. The study doctors want to compare more frequent monitoring vs less frequent
monitoring in order to learn which monitoring method leads to better outcome for patients
with pancreatic cysts. expand
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts. Type: Interventional Start Date: Jun 2020 |
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic...
National Cancer Institute (NCI)
Cholangiocarcinoma
Gallbladder Carcinoma
Stage III Gallbladder Cancer AJCC v8
Stage III Hilar Cholangiocarcinoma AJCC v8
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
This phase I/II trial studies the best dose and side effects of peposertib and to see how
well it works with avelumab and hypofractionated radiation therapy in treating patients
with solid tumors and hepatobiliary malignancies that have spread to other places in the
body (advanced/metastatic). Peposertib... expand
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies. Type: Interventional Start Date: Apr 2020 |
Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes
VA Office of Research and Development
Diabetes Mellitus, Type 2
Hypoglycemia
More than 25% of the patients admitted in the general wards have a history of Diabetes
Mellitus (DM). Up to 30% of the hospitalized diabetics develop hypoglycemia (low glucose
values); a condition that is associated with seizures, cardiac arrhythmias, and even
death. In Veterans, the prevalence is... expand
More than 25% of the patients admitted in the general wards have a history of Diabetes Mellitus (DM). Up to 30% of the hospitalized diabetics develop hypoglycemia (low glucose values); a condition that is associated with seizures, cardiac arrhythmias, and even death. In Veterans, the prevalence is disproportionally higher. It is estimated that 40-50% of hospitalized Veterans are diabetics. In this clinical trial the investigators describe the development of a novel system, the Glucose Telemetry System (GTS), with which glucose values can be wirelessly transmitted from the patient's bedside to a monitor device at the nursing station. The goal of this work is to develop a more effective glucose surveillance system at the general wards, which can decrease hypoglycemia in the hospital and improve clinical outcomes. Type: Interventional Start Date: Jul 2018 |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by...
ECOG-ACRIN Cancer Research Group
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
This randomized phase III trial studies how well crizotinib works in treating patients
with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a
mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in
ALK can make it very active and important... expand
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Type: Interventional Start Date: Mar 2015 |
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
The purpose of this platform study is to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors
combined with Standard(s) of Care (SOC) or with each other.
The first two subprotocols include the following:
Subprotocol A: RMC-6291... expand
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first two subprotocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC Type: Interventional Start Date: Jan 2024 |
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder...
Ironwood Pharmaceuticals, Inc.
Interstitial Cystitis
Bladder Pain Syndrome
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of
interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to
answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder
burning, pressure and discomfort).... expand
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance. Type: Interventional Start Date: Mar 2023 |
Hybrid Type I Effectiveness-Implementation Trial of Project nGage
University of Chicago
HIV Seropositivity
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project
nGage, an evidence-based, flexible, and tailored intervention that leverages existing
social network members to promote retention in care and viral suppression among young
Black sexual minority men (YBSMM) aged 18-35. expand
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project nGage, an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men (YBSMM) aged 18-35. Type: Interventional Start Date: Feb 2023 |
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NYU Langone Health
Pulmonary Embolism
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare
catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation
alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and
right ventricular dilation. expand
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation. Type: Interventional Start Date: Jul 2023 |
- Previous
- Next